Drugs / MultiStem
MultiStem
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01841632 | Apr 2013 → Dec 2016 | — | Prof. Dr. Marc-H. Dahlke, Ph. D. | Terminated | No outcome recorded |
| Phase 1 | NCT00677859 | Jul 2008 → Oct 2011 | hematopoietic and lymphoid system neoplasm | Healios K.K. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02611609 | Jan 2016 → Sep 2018 | acute respiratory distress syndrome | Healios K.K. | Completed | No outcome recorded |
| Phase 24 trials · 3 missed | ||||||
| Phase 2 | NCT04533464 | Nov 2020 → Dec 2025 | — | Healios K.K. | Unknown | No outcome recorded |
| Phase 2 | NCT03807804 | Jan 2019 → Dec 2021 | adult acute respiratory distress syndrome | Healios K.K. | Completed | Missed primary |
| Phase 2 | NCT01436487 | Oct 2011 → Mar 2015 | ischemic stroke | Healios K.K. | Completed | Missed primary |
| Phase 2 | NCT01240915 | Feb 2011 → Nov 2014 | ulcerative colitis | Pfizer | Completed | Missed primary |
| Phase 2/32 trials · 1 missed | ||||||
| Phase 2/3 | NCT04367077 | Apr 2020 → Jan 2023 | acute respiratory distress syndrome | Healios K.K. | Unknown | No outcome recorded |
| Phase 2/3 | NCT02961504 | Nov 2017 → Mar 2021 | ischemic stroke | Healios K.K. | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT03545607 | Jul 2018 → Sep 2022 | ischemic stroke | Healios K.K. | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MultiStem | “Placebo-Controlled, Double-Blind, Phase 2/3 Efficacy and Safety Trial of HLCM051 (MultiStem®) in Patients With Ischemic Stroke” NCT02961504 ↗ |
| Known as | HLCM051 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03807804 ↗ |
| Known as | invimestrocel | “multipotent adult progenitor cells (invimestrocel) for acute respiratory distress syndrome (ARDS) caused by pneumonia” PMID 37608287 ↗ Aug 2023 |
| Known as | MultiStem(r) | “MultiStem(r) is a new biological product, manufactured from human stem cells obtained from adult bone marrow or other nonembryonic tissue sources.” NCT01240915 ↗ |
| Known as | Pf-05285401 | “MultiStem (Pf-05285401)” NCT01240915 ↗ |
| Modality | Cell therapy | “manufactured from human stem cells obtained from adult bone marrow or other nonembryonic tissue sources.” NCT01240915 ↗ |
| Route | Intravenous | “Patients will receive a single IV infusion of MultiStem® 2 days after HSCT.” NCT00677859 ↗ |